TY - JOUR
T1 - Clinical translation of advanced colonic drug delivery technologies
AU - Awad, Atheer
AU - Madla, Christine M.
AU - McCoubrey, Laura E.
AU - Ferraro, Fabiana
AU - Gavins, Francesca K.H.
AU - Buanz, Asma
AU - Gaisford, Simon
AU - Orlu, Mine
AU - Siepmann, Florence
AU - Siepmann, Juergen
AU - Basit, Abdul W.
N1 - Funding Information:
This project has received funding from the Interreg 2 Seas programme 2014–2020 co-funded by the European Regional Development Fund under subsidy contract “Site Drug 2S07-033”. Support was also obtained from the Engineering and Physical Sciences Research Council (EPSRC) UK, grant numbers EP/L01646X and EP/S023054/1 at the UCL School of Pharmacy.
Publisher Copyright:
© 2021
PY - 2022/2
Y1 - 2022/2
N2 - Targeted drug delivery to the colon offers a myriad of benefits, including treatment of local diseases, direct access to unique therapeutic targets and the potential for increasing systemic drug bioavailability and efficacy. Although a range of traditional colonic delivery technologies are available, these systems exhibit inconsistent drug release due to physiological variability between and within individuals, which may be further exacerbated by underlying disease states. In recent years, significant translational and commercial advances have been made with the introduction of new technologies that incorporate independent multi-stimuli release mechanisms (pH and/or microbiota-dependent release). Harnessing these advanced technologies offers new possibilities for drug delivery via the colon, including the delivery of biopharmaceuticals, vaccines, nutrients, and microbiome therapeutics for the treatment of both local and systemic diseases. This review details the latest advances in colonic drug delivery, with an emphasis on emerging therapeutic opportunities and clinical technology translation.
AB - Targeted drug delivery to the colon offers a myriad of benefits, including treatment of local diseases, direct access to unique therapeutic targets and the potential for increasing systemic drug bioavailability and efficacy. Although a range of traditional colonic delivery technologies are available, these systems exhibit inconsistent drug release due to physiological variability between and within individuals, which may be further exacerbated by underlying disease states. In recent years, significant translational and commercial advances have been made with the introduction of new technologies that incorporate independent multi-stimuli release mechanisms (pH and/or microbiota-dependent release). Harnessing these advanced technologies offers new possibilities for drug delivery via the colon, including the delivery of biopharmaceuticals, vaccines, nutrients, and microbiome therapeutics for the treatment of both local and systemic diseases. This review details the latest advances in colonic drug delivery, with an emphasis on emerging therapeutic opportunities and clinical technology translation.
KW - 3D printing drug products and medicines
KW - ASACOL 1600
KW - Chronotherapy and drug absorption
KW - Colonic drug targeting
KW - Drug delivery to the large intestine
KW - Gastro resistant film coatings
KW - Inflammatory bowel disease (ulcerative colitis and Crohn's disease)
KW - Mesalazine formulations
KW - Phloral
KW - Polysaccharides and fermentation
UR - http://www.scopus.com/inward/record.url?scp=85121317432&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2021.114076
DO - 10.1016/j.addr.2021.114076
M3 - Review article
C2 - 34890739
AN - SCOPUS:85121317432
SN - 0169-409X
VL - 181
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
M1 - 114076
ER -